Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 10, 2014 - Issue 1
Submit an article Journal homepage
132
Views
11
CrossRef citations to date
0
Altmetric
Reviews

Immunomodulation of malignant melanoma by contact sensitizing agents

Ryan M TrowbridgeCreighton University School of Medicine, Center for Clinical and Translational Science, CRISS II Room 510, 2500 California Plaza, Omaha, NE, 68178, USA
,
Mario V MitkovCreighton University School of Medicine, Center for Clinical and Translational Science, CRISS II Room 510, 2500 California Plaza, Omaha, NE, 68178, USA
,
Mark R PittelkowMayo Clinic Arizona, Scottsdale, AZ, USA
&
Devendra K AgrawalCreighton University School of Medicine, Center for Clinical and Translational Science, CRISS II Room 510, 2500 California Plaza, Omaha, NE, 68178, USACorrespondence[email protected]
Pages 63-76 | Published online: 22 Nov 2013

References

  • Ellis LZ, Cohen JL, High W, Stewart L. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature. Dermatol. Surg. 38(6), 937–946 (2012).
  • Agarwala SS. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res. 20(1), 1–10 (2010).
  • Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst. Rev. 6, CD008955 (2013).
  • Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J.Clin. Oncol. 25(25), 3802–3807 (2007).
  • Malek-Mansour S. Remission of melanoma with D.N.C.B. treatment. Lancet 2(7827), 503–504 (1973).
  • Harland CC, Saihan EM. Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine. Lancet 2(8660), 445 (1989).
  • Trefzer U, Sterry W. Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma. Dermatology (Basel) 211(4), 370–371 (2005).
  • Damian DL, Thompson JF. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. J. Am. Acad. Dermatol. 56(5), 869–871 (2007).
  • Damian DL, Shannon KF, Saw RP, Thompson JF. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J. Dermatol. 50(4), 266–271 (2009).
  • Damian DL, Saw RP. Dramatic regression of cutaneous, nodal, and visceral melanoma metastases. J. Am. Acad. Dermatol. 65(3), 665–666 (2011).
  • Kim YJ. Topical diphencyprone as an effective treatment for cutaneous metastatic melanoma. Ann. Dermatol. 24(3), 373–375 (2012).
  • Damian DL, Thompson JF. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg. Am. J. Clin. Dermatol. 12(6), 403–404 (2011).
  • Hinz T, Ehler LK, Bieber T, Schmid-Wendtner MH. Complete remission of extensive cutaneous metastatic melanoma on the scalp under topical mono-immunotherapy with diphenylcyclopropenone. Eur. J. Dermatol. 23(4), 532–533 (2013).
  • Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 19(5), 275–282 (2009).
  • Bernstein M. A dermatitis caused by ‘di-nitro-chlorbenzole’. Lancet 13, 111–115 (1912).
  • Melanoma of the Skin. In: AJCC Cancer Staging Manual (7th Edition). Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A ( Eds). Springer, NY, USA, 325 (2010).
  • Von Nida J, Quirk C. Successful treatment of in-transit melanoma metastases using topical 2,4-dinitrochlorobenzene. Australas J. Dermatol. 44(4), 277–280 (2003).
  • Terheyden P, Kortum AK, Schulze HJ et al. Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group. J. Cancer Res. Clin. Oncol. 133(7), 437–444 (2007).
  • Wilkerson MG, Connor TH, Wilkin JK. Dinitrochlorobenzene is inherently mutagenic in the presence of trace mutagenic contaminants. Arch. Dermatol. 124(3), 396–398 (1988).
  • Deleve LD. Dinitrochlorobenzene is genotoxic by sister chromatid exchange in human skin fibroblasts. Mutat. Res. 371(1–2), 105–108 (1996).
  • Weisburger EK, Russfield AB, Homburger F et al. Testing of twenty-one environmental aromatic amines or derivatives for long-term toxicity or carcinogenicity. J. Environ. Pathol. Toxicol. 2(2), 325–356 (1978).
  • Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 64(12), 1699–1714 (2009).
  • Bour H, Peyron E, Gaucherand M et al. Major histocompatibility complex class I-restricted CD8+ T cells and class II-restricted CD4+ T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur. J. Immunol. 25(11), 3006–3010 (1995).
  • Pickard C, Smith AM, Cooper H et al. Investigation of mechanisms underlying the T-cell response to the hapten 2,4-dinitrochlorobenzene. J. Invest. Dermatol. 127(3), 630–637 (2007).
  • Grabbe S, Schwarz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol. Today 19(1), 37–44 (1998).
  • Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature 349(6312), 796–799 (1991).
  • Homey B, Alenius H, Muller A et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat. Med. 8(2), 157–165 (2002).
  • Cavani A, Ottaviani C, Nasorri F, Sebastiani S, Girolomoni G. Immunoregulation of hapten and drug induced immune reactions. Curr. opin. Allergy Clin. Immunol. 3(4), 243–247 (2003).
  • Wack C, Kirst A, Becker JC, Lutz WK, Brocker EB, Fischer WH. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response. Cancer Immunol. Immunother. 51(8), 431–439 (2002).
  • Catalona WJ, Taylor PT, Rabson AS, Chretien PB. A method for dinitrochlorobenzene contact sensitization. A clinicopathological study. N. Engl. J. Med. 286(8), 399–402 (1972).
  • Aleksic M, Pease CK, Basketter DA, Panico M, Morris HR, Dell A. Investigating protein haptenation mechanisms of skin sensitisers using human serum albumin as a model protein. Toxicol. In Vitro 21(4), 723–733 (2007).
  • Dyring-Andersen B, Skov L, Lovendorf MB et al. CD4(+) T cells producing interleukin (IL)-17, IL-22 and interferon-gamma are major effector T cells in nickel allergy. Contact Dermatitis 68(6), 339–347 (2013).
  • Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8(5), 337–348 (2008).
  • Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Ann. Rev. Immunol. 27, 485–517 (2009).
  • Mabuchi T, Chang TW, Quinter S, Hwang ST. Chemokine receptors in the pathogenesis and therapy of psoriasis. J. Dermatol. Sci. 65(1), 4–11 (2012).
  • Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. 165(11), 6107–6115 (2000).
  • Acosta-Rodriguez EV, Rivino L, Geginat J et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8(6), 639–646 (2007).
  • Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J.Invest. Dermatol. 115(1), 81–87 (2000).
  • Martiniuk F, Lee DS, Gaspari A et al. Expression of CD70 and the TH17 transcription factor RORgammaT in human contact dermatitis. J. Drugs Dermatol. 7(10), 956–960 (2008).
  • Zhao Y, Balato A, Fishelevich R, Chapoval A, Mann DL, Gaspari AA. Th17/Tc17 infiltration and associated cytokine gene expression in elicitation phase of allergic contact dermatitis. Br. J. Dermatol. 161(6), 1301–1306 (2009).
  • Larsen JM, Bonefeld CM, Poulsen SS, Geisler C, Skov L. IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis. J. Allergy Clin. Immunol. 123(2), 486–492 (2009).
  • Nosbaum A, Rozieres A, Balme B, Goujon C, Nicolas JF, Berard F. Blocking T helper 1/T helper 17 pathways has no effect on patch testing. Contact Dermatitis 68(1), 58–59 (2013).
  • Muranski P, Boni A, Antony PA et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112(2), 362–373 (2008).
  • Hoffmann R, Wenzel E, Huth A et al. Growth factor mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. Acta Derm. Venereol. 76(1), 17–20 (1996).
  • Lin BW, Jiao ZL, Fan JF et al. Inhibitory effect of melanoma differentiation associated gene-7/interleukin-24 on invasion in vitro of human melanoma cancer cells. J.Korean Med. Sci. 28(6), 833–839 (2013).
  • Ghislin S, Obino D, Middendorp S, Boggetto N, Alcaide-Loridan C, Deshayes F. LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro. BMC cancer 12, 455 (2012).
  • Griffiths CE, Nickoloff BJ. Keratinocyte intercellular adhesion molecule-1 (ICAM-1) expression precedes dermal T lymphocytic infiltration in allergic contact dermatitis (Rhus dermatitis). Am. J. Pathol.135(6), 1045–1053 (1989).
  • Von Moos S, Johansen P, Waeckerle-Men Y et al. The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy 67(5), 638–646 (2012).
  • Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J. Invest. dermatol. 108(6), 914–919 (1997).
  • Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 24(1), 19–28 (2006).
  • Martiniuk F, Damian DL, Thompson JF, Scolyer RA, Tchou-Wong KM, Levis WR. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone. J. Drugs Dermatol. 9(11), 1368–1372 (2010).
  • Van Der Steen P, Van De Kerkhof P, Der Kinderen D, Van Vlijmen I, Happle R. Clinical and immunohistochemical responses of plantar warts to topical immunotherapy with diphenylcyclopropenone. J. dermatol. 18(6), 330–333 (1991).
  • Hunter N, Shaker O, Marei N. Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers. J. Dermatol. Treat. 22(1), 2–10 (2011).
  • Byrne KT, Cote AL, Zhang P et al. Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J. Clin. Invest. 121(5), 1797–1809 (2011).
  • Eriksen K. Treatment of the common wart by induced allergic inflammation. Dermatologica 160(3), 161–166 (1980).
  • Yu X, He J, Mongkhoune S et al. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8(+) CD28(+) T lymphocyte responses. Asian Pac. J. Trop. Med. 6(6), 467–472 (2013).
  • Sun BK, Tsao H. Small RNAs in development and disease. J. Am. Acad. Dermatol. 59(5), 725–737; quiz 738–740 (2008).
  • Vennegaard MT, Bonefeld CM, Hagedorn PH et al. Allergic contact dermatitis induces upregulation of identical microRNAs in humans and mice. Contact Dermatitis 67(5), 298–305 (2012).
  • Felicetti F, Errico MC, Segnalini P, Mattia G, Care A. MicroRNA-221 and -222 pathway controls melanoma progression. Expert Rev. Anticancer Ther. 8(11), 1759–1765 (2008).
  • Pazoki-Toroudi H, Ajami M, Babakoohi S et al. Effects of diphencyprone on expression of Bcl-2 protein in patients with alopecia areata. Immunopharmacol. Immunotoxicol. 32(3), 422–425 (2010).
  • Simonetti O, Lucarini G, Bernardini ML, Simoncini C, Biagini G, Offidani A. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study. Br. J. Dermatol. 150(5), 940–948 (2004).
  • Holzer AM, Kaplan LL, Levis WR. Haptens as drugs: contact allergens are powerful topical immunomodulators. J. Drugs Dermatol. 5(5), 410–416 (2006).
  • Weltzien HU, Moulon C, Martin S, Padovan E, Hartmann U, Kohler J. T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology 107(2), 141–151 (1996).
  • Westerhof W, Manini P, Napolitano A, D'ischia M. The haptenation theory of vitiligo and melanoma rejection: a close-up. Exp. Dermatol. 20(2), 92–96 (2011).
  • Overwijk WW, Lee DS, Surman DR et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl Acad. Sci. USA 96(6), 2982–2987 (1999).
  • Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J.Clin. Oncol. 22(3), 403–415 (2004).
  • Chang AE, Redman BG, Whitfield JR et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8(4), 1021–1032 (2002).
  • Lee P, Wang F, Kuniyoshi J et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J.Clin. Oncol. 19(18), 3836–3847 (2001).
  • Disis ML, Schiffman K, Gooley TA, Mcneel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 6(4), 1347–1350 (2000).
  • Hofbauer GF, Schaefer C, Noppen C et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am. J. Pathol. 151(6), 1549–1553 (1997).
  • Pritchard DJ, Ritts RE Jr, Taylor WF, Miller GC. A prospective study of immune responsiveness in human melanoma. I. Assessment of initial pretreatment status with stage of disease. Cancer 41(6), 2165–2173 (1978).
  • Camacho ES, Pinsky CM, Braun DW Jr et al. DNCB reactivity and prognosis in 419 patients with malignant melanoma. Cancer 47(10), 2446–2450 (1981).
  • Roses DF, Campion JF, Harris MN, Gumport SL. Malignant melanoma. Delayed hypersensitivity skin testing. Arch. Surg. 114(1), 35–38 (1979).
  • Itakura E, Huang RR, Wen DR, Paul E, Wunsch PH, Cochran AJ. IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Modern pathol. 24(6), 801–809 (2011).
  • Garcia-Hernandez ML, Hernandez-Pando R, Gariglio P, Berumen J. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 105(2), 231–243 (2002).
  • Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19(15), 3477–3482 (2001).
  • Lesiak A, Norval M, Sysa-Jedrzejowska A et al. Elicitation of contact hypersensitivity after repeated suberythemal exposures of humans to solar simulated radiation: number of epidermal Langerhans cells. Contact Dermatitis 57(4), 224–229 (2007).
  • Oliver SJ, Macdonald JH, Harper Smith AD et al. High altitude impairs in vivo immunity in humans. High Alt. Med. Biol. 14(2), 144–149 (2013).
  • Przybilla B, Burg G, Thieme C. Evaluation of the immune status in vivo by the 2,4-dinitro-1-chlorobenzene contact allergy time (DNCB-CAT). Dermatologica 167(1), 1–5 (1983).
  • Damian DL. Topical immunotherapy with diphencyprone for cutaneous metastatic melanoma. Presented at: Clinical Oncology Society of Australia 39th Annual Scientific Meeting. Brisbane, Australia, 13 November 2012.
  • Von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61(6), 1071–1074 (1988).
  • Paul E, Muller I, Renner H, Bodeker RH, Cochran AJ. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional beta-interferon injection. Melanoma Res.13(6), 611–617 (2003).
  • Radny P, Caroli UM, Bauer J et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br. J. Cancer 89(9), 1620–1626 (2003).
  • Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res. 18(6), 405–411 (2008).
  • Defty CL, Marsden JR. Melphalan in regional chemotherapy for locally recurrent metastatic melanoma. Curr. Topics Med. Chem. 12(1), 53–60 (2012).
  • Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int. J. Radiat. Oncol. Biol. Phys. 44(3), 607–618 (1999).
  • Trcka J, Kampgen E, Becker JC, Schwaaf A, Brocker EB. [Immunochemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with dacarbazine (DTIC)]. Hautarzt 49(1), 17–22 (1998).
  • Wolchok JD, Hoos A, O'day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412–7420 (2009).
  • Wilmott JS, Long GV, Howle JR et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18(5), 1386–1394 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.